Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety of camrelizumab in esophageal cancer
ChiCTR2400086732Phase 4Not yet recruiting
- Sponsor
- Chongqing University Affiliated Three Gorges Hospital
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in esophageal cancer, sponsored by Chongqing University Affiliated Three Gorges Hospital. Primary endpoint: Occurrence of grade ≥ 3 immune-related adverse events. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2400086732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086732.